Document Type
Article
Journal Title
Cancer letters
Publication Date
11-18-2009
Volume
285
Abstract
We examined the efficacy of combination treatments utilizing cytotoxic drugs plus inhibitors to members of the ErbB-ERK signal pathway in human prostate cancer (PCa) LNCaP C-81 cells. Under an androgen-reduced condition, 50nM gemcitabine caused about 40% growth suppression on C-81 cells. Simultaneous treatment of gemcitabine plus 10microM AG825 produced 60% suppression (p
MeSH Headings
Androgens, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Apoptosis, Benzothiazoles, Cell Line, Tumor, Cell Proliferation, Deoxycytidine, Dose-Response Relationship, Drug, Down-Regulation, Extracellular Signal-Regulated MAP Kinases, Flavonoids, Humans, Male, Prostatic Neoplasms, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-bcl-2, Quinazolines, Receptor, erbB-2, Time Factors, Tyrphostins, bcl-2-Associated X Protein, bcl-X Protein
ISSN
1872-7980
DOI Link
Recommended Citation
Zhang, Li; Davis, Jeffrey S.; Zelivianski, Stanislav; Lin, Fen-Fen; Schutte, Rachel; Davis, Thomas L.; Hauke, Ralph; Batra, Surinder K.; and Lin, Ming-Fong, "Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment." (2009). Journal Articles: Biochemistry & Molecular Biology. 37.
https://digitalcommons.unmc.edu/com_bio_articles/37
Comments
NOTICE: this is the author’s version of a work that was accepted for publication in Cancer Letters. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Cancer Letters, [VOL#285, ISSUE#1, (2009)] DOI#10.1016/j.canlet.2009.04.041